Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. - Wikidata - awgldk - TriplyDB

Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.

Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.

http://www.wikidata.org/entity/Q39009644

about

Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?Biological features and biomarkers in hepatocellular carcinoma Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.Hepatitis C virus-induced hepatocellular carcinoma Liver cancer: Approaching a personalized care.VEGFA genomic amplification tailors treatment of HCCs with sorafenib A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia.pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.Targeting cellular mRNAs translation by CRISPR-Cas9 Clinical implications of basic research in hepatocellular carcinoma.PI3K/AKT/mTOR-dependent stabilization of oncogenic far-upstream element binding proteins in hepatocellular carcinoma cells.New molecularly targeted therapies against advanced hepatocellular carcinoma: From molecular pathogenesis to clinical trials and future directions.Advances in targeted therapies for hepatocellular carcinoma in the genomic era.Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.Quantification of hepatocellular carcinoma heterogeneity with multiparametric magnetic resonance imaging Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.Predicting responsiveness to sorafenib: can the determination of FGF3/FGF4 amplifications enrich for clinical benefit?Molecular Profiling and Research of Therapeutic Targets.Animal model studies indicate a candidate biomarker for sorafenib treatment of hepatocellular carcinoma.Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.Analysis of microarrays of miR-34a and its identification of prospective target gene signature in hepatocellular carcinoma.A phosphokinome-based screen uncovers new drug synergies for cancer driven by liver-specific gain of nononcogenic receptor tyrosine kinases.TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma.Predicting hepatocellular carcinoma through cross-talk genes identified by risk pathways.Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?Hepatocellular carcinoma

P2860

Q26784218-B064BCAB-57B2-4D0A-8736-EBF290171352 Q26799462-83670CE5-4486-404E-B513-F70D9ABF0EAD Q33728138-A2D54E7C-9741-44BC-86E9-8D3947C1017E Q35619104-AB86FB41-D4BD-4708-81DF-8B3457FDD7B2 Q35824057-25CCE076-AF27-4D24-9619-57B68BDD798E Q35903794-E3326AA2-36CC-4484-89EB-7EC0C9C34C16 Q36248778-C2B5DD28-8C60-45A4-B27F-DDDBF2D22E54 Q36670740-A51250C1-53D1-4A7F-BB94-5951133D8F00 Q36771900-12AFD08D-C324-4461-ADD8-67A31FCE1787 Q37089566-CD0A489C-376E-4191-B42C-9E83FF188B7B Q37289933-BE825C26-EB26-4D23-AE81-02FBDA9D6D33 Q37603821-00BBABC9-3BF6-4E60-BE4E-E4FBFF9F878A Q38282800-58E4BAF6-92D1-4F80-9A06-AD1ABEC36D6A Q38521011-657D9A0D-6FF6-4268-AF21-8B6A8E7CEA55 Q38671883-FE3FB705-33F9-41D7-BFD3-567ADE3E5B87 Q38760629-F6B0D679-4916-4D24-B548-331DC6B5F9DE Q41563253-1870DDDD-5041-402A-9E3A-171FEA9CF34E Q41761530-0AFB52FC-C923-4F17-A0B1-8216EA98758E Q41874690-689750CD-AA30-4979-B4F0-729C9068C88B Q42731069-F2BED633-34C6-4DF5-B7FA-0B121B84A00E Q47102809-8FE84220-11F0-439A-A47D-D121BEEEF751 Q47247562-975A896E-447E-4E4D-A9D0-C7B016F98159 Q48321277-05D0D3B6-C1A4-4674-A3C4-1852E796411B Q52779937-103F1967-078B-4C14-9922-FEF94408CDC4 Q55008075-3F7AEF81-1378-433E-8109-884A3B695DAB Q55035102-EDB412C8-9C81-43E1-8D3E-454CDA7D2AFF Q57067866-509A1F25-7E38-42A8-B75F-F591853D96BF Q57756376-AC88F67C-C33E-4877-B501-CF3ACFADF342

P2860

Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.

http://www.wikidata.org/entity/Q39009644

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Human and mouse VEGFA-amplifie ...... sitive to sorafenib treatment.

@en

Human and mouse VEGFA-amplifie ...... sitive to sorafenib treatment.

@nl

type

label

Human and mouse VEGFA-amplifie ...... sitive to sorafenib treatment.

@en

Human and mouse VEGFA-amplifie ...... sitive to sorafenib treatment.

@nl

prefLabel

Human and mouse VEGFA-amplifie ...... sitive to sorafenib treatment.

@en

Human and mouse VEGFA-amplifie ...... sitive to sorafenib treatment.

@nl

P1433

Q39009644-D100AA81-8924-4BE7-B683-E8BCEC625DA6

P1476

Q39009644-137972DA-6619-4333-A0D9-50DE023EFBAB

P2093

Q39009644-091A720D-CF0F-4182-AA1C-A4C7D22F44F3

Q39009644-0BE62857-DA94-43D1-ADAD-C7ECD18A6FB9

Q39009644-10AE87DE-74A7-4640-9A10-5DA17429AF4B

Q39009644-18269CFE-EEE9-4495-B936-BE5F7F67413B

Q39009644-2C58BFE6-AFD5-4A2E-B426-B5CFC8F362B1

Q39009644-3340C930-8829-4464-85FE-DCE027E3C1B5

Q39009644-36091A20-DC4C-49DD-9A21-AFDF15F0B2C4

Q39009644-3767E61B-6088-43E9-BE92-3DE0B78DBAD8

Q39009644-3F9AD24D-8A0E-47E9-9505-E4C1BA407350

Q39009644-617F470E-0343-4608-9683-DD485276BC05

P304

Q39009644-8D685036-213E-4DFF-B0C4-CA46051364DD

P31

Q39009644-DC493D3C-EDA2-42ED-94F0-979D938D3C6F

P356

Q39009644-37FCE493-583B-4923-9070-DAB9C0DFA5F2

P433

Q39009644-3075FF7B-54AE-4BD7-8314-0BA1849341B8

P478

Q39009644-EEC3895A-D5E7-4C36-B7C6-0C4E68D8C820

P50

Q39009644-273F8F18-8893-4F75-B104-3A50E271B0E0

Q39009644-30287F8A-3B21-4411-947B-65D8475D2063

Q39009644-5FA9F384-EA61-483C-8D34-644274145C50

Q39009644-72BD105A-E8FC-4B7E-B6F4-67D9124476BA

P577

Q39009644-AEFC01E8-1E89-4FC3-BA9F-FD412EB6A8D7

P698

Q39009644-78B67ABA-95A3-4819-916B-FD3DEEC9622E

P356

2159-8290.CD-13-0782

P1433

Cancer Discovery

P1476

Human and mouse VEGFA-amplifie ...... nsitive to sorafenib treatment

@en

P2093

Arndt Vogel

http://www.w3.org/2001/XMLSchema#string

Avivit Shoham

http://www.w3.org/2001/XMLSchema#string

Carolin Mogler

http://www.w3.org/2001/XMLSchema#string

Elad Horwitz

http://www.w3.org/2001/XMLSchema#string

Eli Pikarsky

http://www.w3.org/2001/XMLSchema#string

Farid Zreik

http://www.w3.org/2001/XMLSchema#string

Hendrik Reuter

http://www.w3.org/2001/XMLSchema#string

Ilan Stein

http://www.w3.org/2001/XMLSchema#string

Jochen Hess

http://www.w3.org/2001/XMLSchema#string

Julia Nemeth

http://www.w3.org/2001/XMLSchema#string

P304

730-743

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-13-0782

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24687604

http://www.w3.org/2001/XMLSchema#string